1. Signaling Pathways
  2. GPCR/G Protein
  3. Adenylate Cyclase

Adenylate Cyclase

Adenylyl cyclase

Adenylyl cyclases (ACs) are enzymes that catalyze the production of cyclic adenosine monophosphate (cAMP) from adenosine triphosphate (ATP). Adenylyl cyclases integrate positive and negative signals that act through G protein-coupled cell-surface receptors with other extracellular stimuli to finely regulate levels of cAMP within the cell. Humans express nine isoforms of membranous ACs and a soluble AC.

Based on regulatory properties, transmembrane ACs are classified into four groups: Group I: Ca2+/calmodulin-stimulated AC1, AC3, AC8; Group II: Gβγ-stimulated and Ca2+-insensitive AC2, AC4, AC7; Group III: Gαi/Ca2+/PKA-inhibited AC5, AC6; Group IV: forskolin/Ca2+/Gβγ-insensitive AC9. The soluble AC, unlike the transmembrane ACs, is insensitive to hormones, G proteins and forskolin, a diterpene extracted from the root of the plant Coleus forskohlii that directly activates all isoforms of transmembrane ACs except AC9.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-15371
    Forskolin
    Activator 99.92%
    Forskolin (Coleonol) is a potent adenylate cyclase activator with an IC50 of 41 nM and an EC50 of 0.5 μM for type I adenylyl cyclase. Forskolin is also an inducer of intracellular cAMP formation. Forskolin induces differentiation of various cell types and activates pregnane X receptor (PXR) and FXR. Forskolin exerts a inotropic effect on the heart, and has platelet antiaggregatory and antihypertensive actions. Forskolin also induces autophagy.
    Forskolin
  • HY-100396
    SQ22536
    Inhibitor 99.98%
    SQ22536 is an effective adenylate cyclase (AC) inhibitor.
    SQ22536
  • HY-Y1092
    N,N-Dicyclohexylcarbodiimide(DCC)
    Activator 99.75%
    N,N-Dicyclohexylcarbodiimide(DCC) is a dehydrating and condensing agent. N,N-Dicyclohexylcarbodiimide(DCC) enhances adenylate cyclase activity. N,N-Dicyclohexylcarbodiimide(DCC) inhibits amine accumulation. N,N-Dicyclohexylcarbodiimide(DCC) is used to prepare 3-phenylcoumarin derivatives, sulfated derivatives of purslane polysaccharides.
    N,N-Dicyclohexylcarbodiimide(DCC)
  • HY-103193
    NKH477
    Activator 99.86%
    NKH477 (Colforsin dapropate hydrochloride) directly activates the catalytic unit of adenylate cyclase and increases intracellular cAMP. NKH477 is a forskolin derivative that improves cardiac failure mainly through its beneficial effects on diastolic cardiac function. NKH477 exerts an antiproliferative effect in vivo with an altered cytokine profile to inhibit the acute rejection of rat orthotopic lung allografts.
    NKH477
  • HY-135878
    2',5'-Dideoxyadenosine
    Inhibitor 99.86%
    2',5'-Dideoxyadenosine is a potent and non-competitive adenylyl cyclase inhibitor via binding the P-site with an IC50 of 3 µM . 2',5'-Dideoxyadenosine is a nucleoside analog and exerts a potent antiadrenergic action in heart.
    2',5'-Dideoxyadenosine
  • HY-P1544A
    Cerebellin TFA
    Modulator
    Cerebellin TFA is a neuromodulatory hexadecapeptide that serves as a marker for Purkinje cell maturation. Cerebellin TFA stimulates norepinephrine release via the adenylate cyclase/PKA-dependent signaling pathway. Cerebellin TFA reduces insulin secretion from pancreatic islets under high-glucose conditions. Cerebellin TFA also regulates synaptic structure formation and controls catecholamine secretion in peripheral tissues. Cerebellin TFA can be used in neurological research.
    Cerebellin TFA
  • HY-147129
    cGAS-IN-9
    Inhibitor
    cGAS-IN-9 is a cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) inhibitor, with IC50 values of 27.5 nM and 5.15 μM against human and murine cGAS, respectively. cGAS-IN-9 shows weak inhibitory activity against human soluble adenylate cyclase, with an IC50 of 26.4 μM. cGAS-IN-9 inhibits dsDNA-induced expression of IFNB1 and CXCL10, as well as activation of the NF-κB pathway, in human immune cells. cGAS-IN-9 can be used in research related to cGAS-dependent inflammatory diseases.
    cGAS-IN-9
  • HY-137744
    MANT-GppNHp
    Inhibitor
    MANT-GppNHp is a competitive adenyl cyclase (AC) inhibitor. MANT-GppNHp is a fluorescently labeled GTP (HY-113225) analogue. MANT-GppNHp interacts with the hydrophobic pocket near the AC catalytic site through its MANT group, thereby directly blocking the binding of the substrate ATP. MANT-GppNHp can be used to study diseases related to the increased activity of AC (such as cholera).
    MANT-GppNHp
  • HY-103192
    MDL12330A
    Inhibitor 99.82%
    MDL12330A (RMI12330A) is an adenylyl cyclases inhibitor. MDL12330A can inhibit KV channels, increases insulin secretion and Ca2+ levels. MDL12330A accentuates contractions in uterine rings and inhibits cardiac functions. MDL12330A can be used for the research of endocrinology, metabolic and cardiovascular disease .
    MDL12330A
  • HY-101279
    ST034307
    Inhibitor 99.11%
    ST034307 is a potent and selective adenylyl cyclase 1 (AC1) inhibitor, with IC50 of 2.3 μM.
    ST034307
  • HY-151798
    TDI-11861
    Inhibitor 99.35%
    TDI-11861 is an orally active soluble sAC inhibitor optimized and designed based on TDI-10229 (HY-132298), with an IC50 of 3.3 nM and a KD of 1.4 nM. TDI-11861 has advantages such as high affinity, slow dissociation, and good pharmacokinetics. TDI-11861 can be used for research on male contraception and related sAC pharmacology.
    TDI-11861
  • HY-132298
    TDI-10229
    Inhibitor 99.00%
    TDI-10229 is a potent and orally bioavailable inhibitor of soluble adenylyl cyclase (sAC, ADCY10). TDI-10229 displays nanomolar inhibition of sAC in both biochemical and cellular assays (IC50 of 195 nM) and exhibits mouse pharmacokinetic properties sufficient to warrant its use as an in vivo tool compound.
    TDI-10229
  • HY-P1852
    TIP 39, Tuberoinfundibular Neuropeptide
    Activator 99.84%
    TIP 39, Tuberoinfundibular Neuropeptide is an endogenous PTH2 receptor agonist and antihypertensive agent. TIP 39, Tuberoinfundibular Neuropeptide selectively activates the PTH2 receptor with no activity on the PTH1 receptor, stimulates cAMP production, activates adenylate cyclase, and elevates intracellular calcium levels via mobilization from intracellular stores. TIP 39, Tuberoinfundibular Neuropeptide is highly conserved in humans, mice, and rats. TIP 39, Tuberoinfundibular Neuropeptide is applicable to research related to nociception and inflammation-induced pain.
    TIP 39, Tuberoinfundibular Neuropeptide
  • HY-P99509
    Zelminemab
    Inhibitor 98.79%
    Zelminemab (AMG-301) is a humanized monoclonal antibody that inhibits PACAP type I (PAC1) receptor.
    Zelminemab
  • HY-100524
    LRE1
    Inhibitor 99.76%
    LRE1 is a specific and allosteric inhibitor of soluble adenylyl cyclase.
    LRE1
  • HY-103194
    KH7
    Inhibitor 99.0%
    KH7 is a soluble adenylyl cyclase (sAC)-specific inhibitor, with IC50s of 3-10 μM toward both recombinant purified human sACt protein and heterologously expressed sACt in cellular assays. KH7 is also a cAMP inhibitor.
    KH7
  • HY-103430A
    SKF-83566
    Antagonist 99.86%
    SKF-83566 is a potent, blood-brain permeable and orally active D1-like dopamine receptor (D1DR) antagonist and a weaker competitive antagonist at the vascular 5-HT2 receptor (Ki=11 nM). SKF-83566 is a competitive DAT (dopamine transporter) inhibitor with an IC50 of 5.7 μM. SKF-83566 also shows selective inhibition for adenylyl cyclase 2 (AC2) over AC1 and AC5 in the isolated rabbit thoracic aorta. SKF-83566 can be used for research of parkinson’s disease and nicotine craving alleviation.
    SKF-83566
  • HY-100767
    Guanylyl Imidodiphosphate trisodium
    Activator
    Guanylyl Imidodiphosphate (Guanosine 5'-[β,γ-imido]triphosphate) trisodium is a non-hydrolysable GTP analogue, an activator of ADP-ribosylation factor (ARF) and a potent stimulator of adenylate cyclase. Imidodiphosphate trisodium can be used in protein synthesis studies.
    Guanylyl Imidodiphosphate trisodium
  • HY-103185
    CCPA
    Inhibitor 99.77%
    CCPA (2-Chloro-N6-cyclopentyladenosine) a highly selective A1 adenosine receptors agonist with a Ki of 0.4 nM. CCPA inhibits adenylate cyclase with an IC50 of 33 nM. CCPA exhibits anti-seizure and cardiacprotective activity. CCPA can be used for the research of seizure and myocardial infarction.
    CCPA
  • HY-137167
    Guanylyl imidodiphosphate lithium
    Activator 99.86%
    Guanylyl imidodiphosphate lithium (Gpp (NH) p lithium) is a non-hydrolyzable GTP analog. Guanylyl imidodiphosphate lithium increases adenylate cyclase activity. Guanylyl imidodiphosphate lithium binds to and irreversibly activates G proteins.
    Guanylyl imidodiphosphate lithium
Cat. No. Product Name / Synonyms Application Reactivity